abstract |
The present disclosure relates to methods of treating cancer (or tumor) with IL-7 proteins in combination with immune checkpoint inhibitors, such as PD-1 antagonists (e.g., anti-PD-1 antibodies) or CTLA-4 antagonists (e.g., anti-CTLA-4 antibodies). |